Compete remission rates with gemtuzumab ozogamicin (GO) according to use of interleukin 11 (IL-11)
| Cytogenetic finding . | GO without IL-11* . | GO with IL-11† . | Total . |
|---|---|---|---|
| Normal | 2/9 (22) | 7/11 (64) | 9/20 (45) |
| −5/−7 | 0/7 | 0/8 | 0/15 |
| Other abnormal | 0/10 | 2/6 (33) | 2/16 (13) |
| Total | 2/26 | 9/25 | 11/51 (22) |
| Cytogenetic finding . | GO without IL-11* . | GO with IL-11† . | Total . |
|---|---|---|---|
| Normal | 2/9 (22) | 7/11 (64) | 9/20 (45) |
| −5/−7 | 0/7 | 0/8 | 0/15 |
| Other abnormal | 0/10 | 2/6 (33) | 2/16 (13) |
| Total | 2/26 | 9/25 | 11/51 (22) |
Values are numbers (%) of patients.
Two of 20 patients with acute myeloid leukemia (AML), neither of 2 with refractory anemia (RA) with excess of blasts in transformation (RAEB-t), and none of 4 with RA with excess blasts (RAEB).
Seven of 17 patients with AML, 1 of 4 with RAEB-t, and 1 of 4 with RAEB.